Kintara Therapeutics (NASDAQ:KTRA) reported quarterly losses of $(2.10) per share which beat the analyst consensus estimate of $(3.16) by 33.54 percent. This is a 65 percent increase over losses of $(6.00) per share from the same period last year.
Truist Securities Maintains Buy on Spotify Technology, Raises Price Target to $132
Truist Securities analyst Matthew Thornton maintains Spotify Technology (NYSE:SPOT) with a Buy and raises the price target from $115 to $132.
